The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.
Based on a small, preliminary study, an NHGRI-led team concluded that smokers respond quite well to genetic test results provided online — a finding that could have implications for helping smokers kick the habit.
The technology "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.
NCI Director John Niederhuber said last week that the institute plans to expand the Cancer Genome Atlas project to 20 to 25 major tumor types, and to apply next-generation sequencing to at least 100 tumor samples for each of several types of childhood cancers under the TARGET initiative.
Based on the results of the study, the company has assembled a panel of six protein biomarkers with the ability to detect non-small cell lung cancer in patients with 94 percent sensitivity and 93 percent specificity. The company is hoping to launch the test by 2012.